Pharmaceuticals

The Spanish pharma giant secures approval for the first oral antibiotic specifically for acne in China, targeting a multi-billion dollar dermatology market.

Alcami promotes a decade-long leader to COO, a strategic move to harness internal talent and manage its rapid growth in the booming CDMO market.

A new partnership marries AI design with high-throughput lab validation, creating a blueprint to accelerate the creation of new medicines.

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

BioBridges and its legacy brands consolidate into Peritia, a new end-to-end platform designed to accelerate product development for resource-strapped teams.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

Undercover footage shows disturbing treatment of beagles at a Toronto lab, sparking calls for investigation and questioning Canada's animal research laws.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.

As it turns 60, Melmark adds two powerhouse leaders with deep personal ties to its mission, signaling a new era of strategic growth and innovation.

A new AI tool promises to cut SOP updates from days to hours, but how does it stack up in the race to automate regulatory compliance for drug makers?

Amid federal funding threats, state leaders and industry forge a strategic alliance to protect Connecticut’s $7B life sciences sector and fuel innovation.

With the appointment of Kelly Johnston McKee, Science 37 signals a major push to redefine patient experience and operationalize the future of clinical research.

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.

BioTalent Canada's latest awards highlight how inclusivity, diversity, and equity are becoming key drivers of innovation and profit in the bioscience sector.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

China approves Libevitug, a first-in-class drug for the most severe form of hepatitis, marking a major milestone for patients and global biotech innovation.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.